fda glp-1 warning october 2025 issued 25 letters to telehealth companies for false and misleading claims about compounded products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of The New York Times spotlighted

At microdose levels, this risk is likely minimal, but patients with existing gallbladder disease should be monitored

Lanham TN, Morgan FH

Glucagon-like-peptide-1 receptor agonist, like native glucagon-like peptide-1, Exendin-4, and Liraglutide, exert context-, dose-, and timing-dependent effects on human mesenchymal stem cells

Some people taking both medications report virtually no appetite at all, which can make eating feel like a chore rather than an enjoyable part of life

Some post-cholecystectomy patients report increased loose stools or abdominal discomfort when starting semaglutide, because the medication further slows digestion in an intestinal tract that is already managing continuous bile flow